| Rank |
Status |
Study |
| 1 |
Recruiting
|
Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants
| Conditions: |
Urea Cycle Disorders; Organic Acidemias |
| Interventions: |
Other: Therapeutic Hypothermia; Other: Standard of care therapy |
| Outcome Measures: |
Number of Participants with unexpected Serious Adverse Events as a Measure of Safety and Tolerability; Feasibility of hypothermia therapy as adjunct therapy to the complex standard of care therapy; Time to normalization of ammonia level |
|
| 2 |
Recruiting
|
Longitudinal Study of Urea Cycle Disorders
| Conditions: |
Brain Diseases, Metabolic, Inborn; Amino Acid Metabolism, Inborn Errors; Urea Cycle Disorders |
| Intervention: |
|
| Outcome Measures: |
Prevalence of specific morbid indicators of disease severity; Relationship between various biomarkers and disease severity and progression; Safety and efficacy of currently used and new UCD therapies |
|
| 3 |
Not yet recruiting
|
Brain Imaging of Intranasal Oxytocin Treatment in Autism
| Condition: |
Autism Spectrum Disorders |
| Intervention: |
Drug: Oxytocin |
| Outcome Measures: |
Aim 1a. fMRI Activation Analysis/Connectivity; Aim 1b. Proportion of Time Attending to Social Stimuli (Eye Tracking); Plasma Oxytocin (OT) levels in aim 1b. and 2b.; Salivary Oxytocin (OT) levels for aim 1b and 2b.; SRS-Social Responsiveness Scale; Pervasive Developmental Disorders Behavior Inventory-Screening Version (PDDBI-SV); ABC-Lethargy/social withdrawal subscale |
|
| 4 |
Recruiting
|
Proton Radiotherapy for Stage I, IIA, and IIB Seminoma
| Condition: |
Stage I, IIA and IIB Seminoma |
| Intervention: |
Radiation: Proton Radiation Therapy |
| Outcome Measure: |
Number of Serious Adverse Events |
|
| 5 |
Recruiting
|
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
| Condition: |
Pervasive Developmental Disorder |
| Intervention: |
Drug: aripiprazole |
| Outcome Measures: |
Clinical Global Impression - Improvement; Aberrant Behavior Checklist Irritability Scale; The Aberrant Behavior Checklist Lethargy, Stereotypy, Hyperactivity and Inappropriate Speech Subscales |
|
| 6 |
Recruiting
|
Study to Evaluate the Efficacy and Safety of Aripiprazole
| Condition: |
Autism |
| Intervention: |
Drug: Aripiprazole |
| Outcome Measures: |
irritability subscale of the aberrant behavior checklist; Change from baseline in ABC-subscale of Lethargy/social withdrawal, stereotypic behavior, hyperactivity, inappropriate speech; Change of CGI-S, CGI-I from baseline; Change of Behavioral problems from baseline; Change of Adaptive Skills from baseline; Change of Parental stress from baseline |
|
| 7 |
Recruiting
|
Pediatric Autism Study
| Condition: |
Autism |
| Interventions: |
Drug: Lurasidone 20 mg daily; Drug: Lurasidone; Drug: Placebo |
| Outcome Measures: |
Change from Baseline to Week 6 in the ABC irritability subscale; Change from Baseline in Clinical Global Impression severity (CGI-S) scale; Change in Clinical Global Impression Improvement (CGI-I) scale; Change from Baseline in other Aberrant Behavior Checklist (ABC) subscale scores (hyperactivity, stereotypy, inappropriate speech, and Lethargy/social withdrawal); Change from Baseline in Children's Yale-Brown Obsessive Compulsive Scales (CY-BOCS) modified for pervasive developmental disorders (PDDs); Change from Baseline in the Caregiver Strain Questionnaire (CGSQ); Proportion of subjects who have CGI-I score of 1 (very much improved) or 2 (much improved) at Week 6; Proportion of subjects who have at least 25% reduction from Baseline to Week 6 in the ABC irritability subscale score.; Number of Participants with Adverse Event Reporting; Laboratory Tests - actual values and change from Baseline values for each time point measured.; Vital Signs - actual values and change from Baseline values for each time point measured.; Body Weight-Body Mass Index; Waist Circumference; Physical Examination - assessment of general appearance and a review of systems; Height (as measured by stadiometer); Electrocardiogram; Barnes Akathisia Rating Scale (BARS); Abnormal Involuntary Movement Scale (AIMS); Simpson-Angus Scale (SAS); Tanner Staging; Menstrual Cyclicity - Menstrual cyclicity will be monitored in female subjects who have begun menses. At Baseline, female subjects will be given a calendar to mark the beginning and end of each menses. |
|
| 8 |
Unknown †
|
Treatment of Iron Deficiency Anemia in Malaria Endemic Ghana
| Condition: |
Anemia |
| Interventions: |
Dietary Supplement: Sprinkles®; Dietary Supplement: vitamin/mineral fortificant without iron |
| Outcome Measures: |
incidence of clinical malaria (if fever recorded a blood sample will be taken to determine parasite species and count); changes in anemia status (blood levels of: haemoglobin(Hb) , ferritin (SF)); severity of clinical malaria (blood parasite count); cerebral malaria (defined by a parasite count >5000/μL blood and a concurrent score of <2 on the Blantyre coma scale, with or without convulsions); hospitalization (documentation of hospitalization for any reason); death; pneumonia (defined by the presence of a cough or breathing difficulties, tachypnea, lower chest wall indrawing, and the appearance of consolidation or pleural effusion on a chest X-ray); diarrhea (defined by >3 loose or watery stools in the previous 24 hours); dehydration (defined by Lethargy, sunken eyes, and decreased skin turgor [>2 seconds for skin to return following a skin pinch]) |
|
| 9 |
Unknown †
|
Effect of Adjuvant Treatment With Compound Cranberry Extract Tablets in Acute Bacterial Cystitis.
| Conditions: |
Pyuria; Urinary Tract Infections |
| Intervention: |
Drug: compound cranberry extract tablet |
| Outcome Measures: |
Time to symptoms relief; Pyuria eradication rate |
|
| 10 |
Recruiting
|
Supreme-LMA for Neonatal Resuscitation: a Prospective, Randomized Single-center Study
| Condition: |
Neonatal Resuscitation |
| Interventions: |
Device: Supreme LMA; Device: Facial mask |
| Outcome Measures: |
Proportion of newborns needing endotracheal intubation; Time to first breath; Proportion of patients needing Chest compressions and medications; Proportion of patients with hypoxic ischemic encephalopathy |
|
| 11 |
Recruiting
|
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
| Condition: |
Hepatic Encephalopathy |
| Interventions: |
Drug: Rifaximin; Drug: Lactulose |
| Outcome Measures: |
Development of Progressive Hepatic Encephalopathy to Stage 3 or 4 in patients with progressive renal failure; In-hospital mortality; Hospital Length of Stay |
|
